Drug Profile
ALD 601
Alternative Names: ALD-601Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Aldagen
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Lysosomal storage diseases
Most Recent Events
- 03 Apr 2017 Aldagen withdrew a phase I trial prior to enrolment for Lysosomal storage diseases as patients were consented to screening but none were enrolled and proceeded with transplant in USA (Parenteral) (NCT01003912)
- 05 May 2014 Discontinued - Phase-I for Lysosomal storage diseases in USA (Parenteral)
- 08 Feb 2012 Aldagen has been acquired by Cytomedix